RS BioTherapeutics is focused on developing innovative therapies for diseases associated with pulmonary inflammation. Their lead investigational compound, RSBT-001, represents a novel approach to treating respiratory conditions such as Chronic Obstructive Pulmonary Disease (COPD), Idiopathic Pulmonary Fibrosis, and Pulmonary Arterial Hypertension. Unlike traditional corticosteroids, RSBT-001 utilizes the anti-inflammatory properties of specific cannabinoids to modulate the immune response and target the inflammatory processes within the lungs. This multi-faceted approach aims to reduce pulmonary inflammation effectively, offering a potential alternative for patients who may not respond well to existing treatments.

The company is actively working towards filing an Investigational New Drug (IND) application for RSBT-001 by 2026, indicating a commitment to advancing their therapeutic pipeline. RS BioTherapeutics is supported by a leadership team of industry experts and a Therapeutic Expert Council, which underscores their dedication to scientific rigor and innovation in the field of pulmonary medicine. Through these efforts, RS BioTherapeutics aims to make a significant impact on the lives of individuals suffering from debilitating respiratory diseases.

United States

RS BioTherapeutics is a research, development, and commercialization company focused on developing life-changing medicines for pulmonary diseases. The company's mission is to harness the therapeutic power of cannabinoids in the research, development, and commercialization of these medicines.

RS BioTherapeutics

Company Details